Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Eaton Corporation plc (ETN) Price & Performance

ADMA Biologics IncTrade
Eaton Corporation plcTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Eaton Corporation plc — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Eaton Corporation plc trades at $462.58 (market cap $172.82B). The key difference: Eaton Corporation plc is far larger — about 77.8× ADMA Biologics Inc's market cap, and Eaton Corporation plc pays a 0.99% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAETN
Market Cap
$2.22B$172.82B
Sector
HealthTechnology
52-Week High
$20.38$459.29
52-Week Low
$7.60$315.82
Enterprise Value
$2.29B$193.45B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

Eaton Corporation plc

Eaton Corporation (ETN) trades at $468.37, up 5.26% in 24 hours, reflecting strong momentum after recent earnings beats. The stock exhibits a bullish technical trend with support at $456 and resistance at $470. Q2 2026 earnings beat expectations with EPS of $3.15 versus $3.07 estimated, and the company raised its full-year outlook, driven by robust demand in electrical and data center segments.

Outlook remains positive given raised guidance and AI-driven power infrastructure demand, but risks include premium valuation (P/E 45.31) and execution challenges. Analyst consensus is bullish with a $499.75 price target, though investors should monitor competitive pressures and macroeconomic conditions affecting industrial spending.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Eaton Corporation plc

Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.

Read more on ETN